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Nathaniel I. Keymer,a Niklaas J. Buurma a and Simon J. A. Pope *a
A nuclear localisation sequence (NLS) peptide, PAAKRVKLD, derived from the human c-Myc regulator gene,
has been functionalised with a long wavelength (lex ¼ 550 nm; lem ¼ 677 nm) cyclometalated
organometallic iridium(III) complex to give the conjugate Ir-CMYC. Confocal ﬂuorescence microscopy
studies on human ﬁbroblast cells imaged after 18–24 h incubation show that Ir-CMYC concentrations of
80–100 mM promote good cell uptake and nuclear localisation, which was conﬁrmed though co-
localisation studies using Hoechst 33342. In comparison, a structurally related, photophysically
analogous iridium(III) complex lacking the peptide sequence, Ir-PYR, showed very diﬀerent biological
behaviour, with no evidence of nuclear, lysosomal or autophagic vesicle localisation and signiﬁcantly
increased toxicity to the cells at concentrations >10 mM that induced mitochondrial dysfunction.
Supporting UV-visible and circular dichroism spectroscopic studies show that Ir-PYR and Ir-CMYC
display similarly low aﬃnities for DNA (ca. 103 M1), consistent with electrostatic binding. Therefore the
translocation and nuclear uptake properties of Ir-CMYC are attributed to the presence of the
PAAKRVKLD nuclear localisation sequence in this complex.Introduction
A signal peptide is a short peptide sequence oen present at the
N-terminus of newly synthesised proteins that is responsible for
intra- and extracellular translocation.1 When that translocation
target is the cell nucleus such a peptide can facilitate transport
of macromolecules between the cytoplasm and the nucleus and
is referred to as a nuclear localisation signal (NLS).2 The best
characterised mechanisms for protein import across the
nuclear envelope are described for the “classical” NLSs, which
consists of either one (PKKKRKV) or two (KRPAATKKAG-
QAKKKK) amino acid sequences.3 Previous research has shown
that >50% of nuclear proteins conform to these sequences.4
We were interested in an alternative NLS peptide sequence
(PAAKRVKLD) which is derived from the human c-Myc protein
(residues 320–328) and was rst identied in 1988 to be
essential for nuclear localisation of the protein.5 The
PAAKRVKLD sequence is somewhat unusual as a NLS becauseMain Building, Cardiﬀ, CF10 3AT, UK.
ir Martin Evans Building, Cardiﬀ, UK
(ESI) available: Experimental synthetic
physical data and DNA binding data.
of Chemistry 2020three of its residues are cationic at physiological pH.5 The c-Myc
protein is the transcription regulator expressed from the c-Myc
gene, whose constitutive expression in cancer is associated with
increased expression of other genes involved in cell prolifera-
tion, contributing to cancer development.6 It is tightly regulated
in non-cancerous cells, but is now understood to be a frequently
deregulated oncogene.7 Therefore c-Myc is of interest when
considering approaches to targeted cancer therapy.8 Fusion
proteins of the c-Myc NLS with b-galactosidase have also been
used as a positive control for the identication of other nuclear
localisation sequences,9 and in the production of light-
inducible nuclear localisation sequences for tracking protein
dynamics in live cells.10 Recently, a study described how green
uorescent protein (GFP) loaded nanoparticulate assemblies
have been used to deliver proteins directly to the cytosol of cells.
Conjugation of GFP with a variety of NLSs enabled observable
traﬃcking of the protein to the nucleus using confocal uo-
rescence microscopy.11 These results showed that the c-Myc NLS
conjugate produced the highest relative intensity of uores-
cence in the nucleus versus the cytosol.
In this study, we wished to visualise the cellular trans-
localisation characteristics of the c-Myc NLS (PAAKRVKLD) in
human broblast cells. To do this we investigated the use of
a deep red luminescent organometallic complex as an optical
label for the c-Myc NLS, which we envisaged would be advan-
tageous when applied to confocal uorescence microscopy. TheChem. Sci.
Scheme 1 Structures of the luminescent complexes Ir-COOH, Ir-PYR
and Ir-CMYC, investigated during this study.
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View Article Onlinepotential of luminescent transition metal complexes (e.g. based
upon Ru(II), Re(I), Ir(III) and Pt(II)) for cellular bioimaging has
been explored over the last decade.12 In some cases metal
complexes functioning as probes for cellular dysfunction have
also been investigated.13 However, in biological and bioimaging
studies it is notoriously diﬃcult to predict the intracellular
localisation behaviour of such species because of the chal-
lenging interplay of charge, hydro- and lipophilicity, structure–
function relationships, and cytotoxicities.14 This in turn makes
the rational design of organometallic bioimaging probes
extremely challenging. The use of targeting vectors is one way to
address this challenge.
Only a small number of reports have detailed the use of
signal peptide conjugates of luminescent coordination
complexes. Examples include rhenium(I) bisquinoline
complexes for targeting the folate receptor of cancer cells,15 and
99mTc(I) labelled compounds to investigate targeting of radio-
imaging (and therapeutic) agents.16 Polypyridine complexes of
Ru(II) have been the most developed in this area. Keyes and co-
workers have reported a cell permeable polyarginine–Ru(II)
complex possessing triplet metal-to-ligand charge transfer
(3MLCT) emission behaviour and associated oxygen quenching
sensitivity.17 Subsequent studies by the same group have
described multimodal variants,18 peptide bridged dinuclear
Ru(II) complexes for monitoring oxygen concentration in cells,19
and nuclear targeting with a NLS (VQRKRQKLMP) Ru(II)
conjugate20 leading to photoinduced DNA destruction.21 Related
1,4,5,8-tetraazaphenanthrene (TAP) ligands on Ru(II) have also
been studied, because of their photooxidising properties that
can induce signicant DNA damage, although interestingly the
phototoxicity can be strongly inhibited by peptide
(VQRKRQKLMP) conjugation of the complex.22 The cell nucleus
is clearly an attractive target when considering the delivery of
phototherapeutic action and transition metal complexes,
particularly those of the 4th and 5th rows, have long been
investigated for applications to photodynamic therapy (PDT).23
Herein we present an example of a peptide functionalised
luminescent Ir(III) complex, and, to the best of our knowledge,
the rst small molecule luminescent moiety to feature a c-Myc
inspired NLS. Together with an appropriately designed struc-
tural variant that lacks the NLS, this study demonstrates that
the c-Myc NLS enables transport of the Ir(III) conjugate into the
nucleus of human broblast cells.Results and discussion
Synthesis of the NLS peptide and the Ir(III) complexes
The adopted strategy was to conjugate an organometallic iri-
dium(III) complex entity to the N-terminus of the peptide via an
amide bond whilst retaining the intrinsic luminescent proper-
ties of the complex. The cyclometalated iridium(III) complexes
(Scheme 1) were synthesised according to previous methods
described for related systems.24 Thus, the diuorinated qui-
noxaline ligand (6,7-diuoro-2-methyl-3-phenylquinoxaline)
was used as a cyclometalating ligand to form the dimetallic
precursor [(L)2Ir(m-Cl)2Ir(L)2], which was then split using 4-Chem. Sci.methyl-2,20-bipyridine-4-carboxylic acid to give monometallic Ir-
COOH.
For the PAAKRVKLD sequence, Fmoc-solid phase peptide
synthesis was performed using the Rink amide resin
(0.19 mmol g1 loading) at 0.1 mmol scale using standard
techniques. Coupling was performed using 5.0 eq. O-(benzo-
triazol-1-yl)-N,N,N0,N0-tetramethyluronium hexa-
uorophosphate, 5.0 eq. 1-hydroxybenzotriazole, N,N-
diisopropylethylamine and 4.0 eq. of amino acid. Single
coupling was performed for 60 min, while double coupling was
carried out for 45 min per cycle for arginine and valine and their
direct successive amino acids. Subsequent Fmoc deprotection
was achieved using standard conditions (see Experimental) to
aﬀord the crude peptide attached to the resin. Ir-COOH was
then coupled in identical conditions to aﬀord the crude iridium
peptide complex. The crude iridium–peptide complex was
cleaved oﬀ the resin by stirring in (v/v/v/v) 92.5 : 2.5 : 2.5 : 2.5
TFA/water/DODT/TIS (where TFA ¼ triuoroacetic acid, DODT
¼ 2,20-(ethylenedioxy)diethanethiol, TIS ¼ triisopropylsilane)
for 2 hours at room temperature to yield 5 mg of crude conju-
gate. LC-MS analysis using a linear gradient of 10% to 95%
acetonitrile–water (+0.1% TFA) over 13 min revealed the crude
Ir-CMYC which eluted at 8.0 min, with the molecular compo-
sition of the iridium–peptide complex conrmed by LC-MS with
observedm/z¼ 947 and 632, corresponding to the [M + H]2+ and
[M + 2H]3+ of Ir-CMYC, respectively. The crude conjugate was
puried via preparatory HPLC (Fig. S2 and S3, ESI†) under an
identical gradient eluting at 28.6 min, prior to lyophilization
yielding 1.5 mg of pure Ir-CMYC. The lyophilized Ir-CMYC was
subsequently used for all characterization and biological
testing.
An additional iridium(III) complex lacking the peptide
sequence, Ir-PYR, was also synthesised for investigation as
a photophysical analogue of Ir-CMYC. Thus, 4-methyl-2,20-This journal is © The Royal Society of Chemistry 2020
Fig. 1 UV-vis absorption and emission spectra of Ir-PYR (dashed line)
and Ir-CMYC (solid line).
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View Article Onlinebipyridine-4-carboxylic acid was simply converted to 40-methyl-
(2,20-bipyridine)-4-(pyrrolidin-1-yl)methanone to give a new
bipyridine derivative (see ESI† for experimental procedure), and
then in turn reacted with [(L)2Ir(m-Cl)2Ir(L)2] to give the pyrro-
lidine terminated species Ir-PYR. Ir-PYR was puried using
preparatory HPLC (Fig. 1, ESI) and characterised using the
standard array of techniques: 1H NMR data was particularly
insightful, revealing the three unique methyl proton environ-
ments (two from the inequivalent quinoxalines, one from the
bipyridine), as well as the pyrrolidine protons at 3.2–1.8 ppm.
High resolution MS was also obtained conrming the parent
cation with the correct isotopic distribution at m/z ¼ 968.2446
(Fig. S1, ESI†).Fig. 2 Confocal microscopy shows Ir-PYR to produce cytoplasmic
punctate staining. Ir-PYR (red, (B)) was incubated with human ﬁbro-
blasts at a concentration of 5 mM for 18 hours, and the nuclei with
Hoechst 33342 (blue, (A)). Merged channels (C) demonstrate the lack
of Ir-PYR nuclear co-localization, as represented in a sample co-
localization plot (D) showing the relative ﬂuorescent units (RFU) of
both Ir-PYR (red) and Hoechst 33342 (blue) across a cell. Represen-
tative scale bar in (A) is equal to 7.5 mm.Photophysical characterisation of Ir-PYR and Ir-CMYC
Our previous studies on Ir(III) complexes have shown that the
use of substituted, cyclometalated quinoxaline ligands can
impart red luminescence characteristics.25 Firstly, the UV-vis
absorption and emission spectral characteristics of Ir-PYR
were determined. The absorption spectrum was obtained in
water and showed a composite of bands between 200–600 nm;
the appearance of the spectrum is reminiscent of closely
related [Ir(C^N)2(N^N)]
+ complexes of this type.26 By infer-
ence, ligand-centred transitions are assumed to dominate
below 350 nm, with both quinoxaline and bipyridine located
p / p* contributing to the spectrum. At 350–450 nm it is
likely that spin-allowed metal-to-ligand (5d-to-p*) charge
transfers (1MLCT) are present, with a weaker (3 <
1000 M1 cm1) shoulder feature at 450–600 nm, which is
presumably due to a spin forbidden (S0 / T1)
3MLCT
absorption. The corresponding absorption spectrum for the
peptide functionalised species Ir-CMYC shares the same
features with Ir-PYR, showing that the addition of the peptide
sequence does not dramatically alter the intrinsic electronic
properties of the complex. To assess longer term stability in
water, UV-vis absorption spectra of an aqueous solution
(stored at 25 C in light) of Ir-CMYC were recorded at 0, 24, 48
and 72 h (Fig. S4, ESI†). The resultant spectra were superim-
posable suggesting not only good chemical stability, but also
excellent solubility.This journal is © The Royal Society of Chemistry 2020The luminescence properties of the Ir(III) complexes (Fig. 1)
were determined in dilute aerated aqueous solvent. Initially, an
excitation wavelength of 550 nm was adopted which is selective
for the MLCT absorption bands of the complex, and resulted in
a broad emission peak (lem) for Ir-PYR centred at 674 nm (cf. Ir-
COOH lem ¼ 673 nm). The long wavelength emission charac-
teristics are consistent with our previous studies on cyclo-
metalated quinoxaline [Ir(C^N)2(N^N)]
+ complexes of Ir(III).25
The modest bathochromic shi is likely induced by the polar
nature of the water solvent, which in turn suggests a 3MLCT
contribution to the emitting state. For Ir-PYR time-resolved
measurements gave the corresponding lifetime (sobs) at 42 ns,
and a quantum yield assessment gave ca. 3%, which is typical
for this class of compound in aerated solvent. The phospho-
rescent nature of Ir-PYR was demonstrated by a recorded life-
time of 353 ns in MeCN (Fig. S5, ESI†). Luminescence
spectroscopy on Ir-CMYC gave comparable data (Fig. 1), with
lem ¼ 677 nm (sobs ¼ 38 ns), thus conrming that the photo-
physical properties of the Ir(III) complex moiety are retained
aer functionalisation with the peptide sequence.Cell imaging with Ir-PYR and Ir-CMYC
The non-peptide functionalised complex Ir-PYR was investi-
gated at a range of concentrations (1, 5, 20, 50, 80, 100 mM) with
respect to cell uptake, localization and bioimaging capability.
Human broblast cells were incubated with the diﬀerent
concentration solutions of Ir-PYR and imaged aer 18 hoursChem. Sci.
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View Article Onlineusing confocal uorescence microscopy. With long wavelength
excitation and emission parameters (lex ¼ 480 nm; lem ¼ 645
nm) compatible with the spectral properties of the complex, it
was clearly evident (Fig. 2) that the deep red emission of Ir-PYR
was highly amenable to confocal uorescence microscopy.
At lower concentrations Ir-PYR showed punctate staining of
the cells, but with no evidence for nuclear localization (Fig. 2),
whereas at 50–100 mM the compound appeared to be very toxic,
as evidenced by reduced cell number and mitochondrial
dysfunction (Fig. 3).27 A series of co-localization imaging
experiments revealed that Ir-PYR does not localise in the
nucleus, lysosomes or autophagic vesicles (Fig. 4).
Having demonstrated that Ir-PYR does not localize in the cell
nucleus, further imaging studies were then conducted on the
peptide-functionalised analogue, Ir-CMYC. Again, a series of
concentrations were used (1, 5, 20, 50, 80, 100 mM) for incuba-
tion with the cells. No uptake or staining was observed for 1–5
mM Ir-CMYC, but with increasing concentrations there was very
clear uptake and staining evident (Fig. 5).Fig. 3 Ir-PYR is cytotoxic at 20 mMand above. Human ﬁbroblasts were
incubated with various concentrations (0 or DMSO only, 5, 20, 50, 80,
100 mM) of either Ir-CMYC (A) or Ir-PYR (B) for 18 hours. Resazurin was
added to cells, and after a 4 hour incubation the relative ﬂuorescence
intensity was measured (lex ¼ 530 nm; lem ¼ 580 nm). Ir-PYR treated
cells (>20 mM) show reduced conversion of resazurin to the ﬂuores-
cent resoruﬁn indicating reduced cell viability. No cytotoxicity was
observed at any Ir-CMYC concentration.
Fig. 4 Confocal scanning microscopy shows Ir-PYR does not co-
localize with nuclei, lysosomes or autophagic vesicles. Ir-PYR (red, (C))
was incubated with human ﬁbroblasts at 5 mM for 18 hours and co-
stained with Hoechst 33342 (blue, (A)) and either LysoTracker green
(top row, (B)) or CYTO-ID (second row, (B)). Merged channels (D)
demonstrate the lack of Ir-PYR co-localization with any utilised
counterstain. Representative scale bar in (A) is equal to 7.5 mm.
Chem. Sci.At 20–50 mM weak punctate staining was observed
throughout the cytoplasm, and at 80–100 mM strong staining
was seen throughout the cell, with clear nuclear localization.
Co-localization experiments using Hoechst 33342 demonstrate
that Ir-CMYC does enter and localize in the cell nucleus (Fig. 5).
At 24 hours aer Ir-CMYC incubation, there were no detectable
changes in cellular morphology or mitochondrial activity (as
monitored by a resazurin cell death assay) indicating no (or
minimal) toxicity of Ir-CMYC to the cells.
In view of the nuclear localisation of Ir-CMYC, we also
considered the potential role that aﬃnity to DNA may play. To
explore DNA binding of these Ir(III) complexes, UV-vis and
circular dichroism titrations were carried out in buﬀer (25 mM
MOPS, 50 mM NaCl, 1 mM EDTA) at 25 C (Fig. S6, ESI†). To
quantify the aﬃnity of Ir-PYR for sh sperm DNA, titration
curves at 400 and 493 nm were extracted from the circular
dichroism data (Fig. 6). Similarly, for Ir-CMYC, titration curves
at 373 and 493 nm were extracted from the circular dichroism
data. The binding data were analysed globally (Table S1†) in
terms of the multiple independent binding sites model,
explicitly taking into account the dilution of the iridium
complex during the titration.28 This analysis gave binding
constants of (1.5  0.7)  103 M1 and (4.5  1.0)  103 M1 for
Ir-PYR and Ir-CMYC, respectively (full tting details in the ESI†).
Although Ir-CMYC appears to bind a bit more strongly to DNA
than Ir-PYR, the diﬀerence is less than an order of magnitude
and both aﬃnities are low. Indeed such low values are indica-
tive of an interaction with DNA which is driven by electrostatics,
suggesting that neither the c-Myc NLS or the cationic Ir(III)
complex moiety strongly interact with the DNA structure.
To investigate whether the NLS was cleaved oﬀ Ir-CMYC prior
to translocation to the nucleus, an immunoassay was trialled
using an antibody raised against c-Myc. Following theFig. 5 The addition of the c-Myc tag results in a signiﬁcantly greater
degree of nuclear co-localization. Ir-CMYC (red, (B)) was incubated
with human ﬁbroblast at a range of concentrations (50, 80 & 100 mM)
for 18 hours prior to counterstaining with Hoechst 33342 (grey, (A)).
Merged images (C) show nuclear co-localization at concentrations of
80 and 100 mM. Sample co-localization plots (D) show the intensity in
relative ﬂuorescent units (RFU) of Ir-CMYC (red) and Hoechst 33342
(grey) across a cell. Representative scale bar in (A) is equal to 7.5 mm,
images acquired at (lex ¼ 480 nm; lem ¼ 645 nm).
This journal is © The Royal Society of Chemistry 2020
Fig. 6 Ir-PYR and Ir-CMYC both interact weakly with DNA. Circular
dichroism titration of Ir-PYR (top) with ﬁsh sperm DNA, 400 nm (C),
493 nm (:); titration for Ir-CMYC (bottom), 373 nm (C), 493 nm (:).
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View Article Onlineimmunocytochemistry procedure which permeabilises the cell
membrane, the red emission from Ir-CMYCwas no longer evident
in the cells using uorescence microscopy imaging. This suggests
that permeabilisation of the cell membrane causes Ir-CMYC to
leak out of the cell consistent with not being bound to DNA.
Taken together, these results suggest that the fundamental
diﬀerences in nuclear localisation observed between Ir-PYR and
Ir-CMYC cannot be explained in terms of an aﬃnity for DNA:
the nuclear localisation of Ir-CMYC is facilitated by the
PAAKRVKLD sequence.Conclusion
In summary, the synthesis, spectroscopic properties and cellular
translocation characteristics of a deep red luminescent organo-
metallic Ir(III) complex conjugated with a c-Myc NLS have been
described. The NLS conjugated complex is essentially non-toxic,
which contrasts strongly with the non-peptide complex analogue,
which induces mitochondrial dysfunction and is toxic $20 mM.
The conjugated complex was demonstrated, viaUV-vis and circular
dichroism titrations, to have a very weak aﬃnity for DNA (4.5 
103 M1). Therefore, through a range of biological and spectro-
scopic studies it was demonstrated that the c-Myc nuclear locali-
zation sequence PAAKRVKLD promotes nuclear uptake of an
organometallic iridium(III) complex in human broblast cells.Experimental
General considerations
All reagents and solvents were commercially available and were
used without further purication if not stated otherwise. For the
measurement of 1H, 31P, and 13C NMR spectra a Bruker Four-
ier300 (300 MHz), Bruker AVANCE HD III equipped with a BFFO
SmartProbe™ (400 MHz) or Bruker AVANCE III HD with BBOThis journal is © The Royal Society of Chemistry 2020Prodigy CryoProbe (500 MHz) was used. The obtained chemical
shis d are reported in ppm and are referenced to the residual
solvent signal. Spin–spin coupling constants J are given in Hz.
Low-resolution mass spectra were obtained by the staﬀ at
Cardiﬀ University. High resolution mass spectral (HRMS) data
were obtained on a Waters MALDI-TOF mx at Cardiﬀ Univer-
sity or on a Thermo Scientic LTQ Orbitrap XL by the EPSRC UK
National Mass Spectrometry Facility at Swansea University. IR
spectra were obtained from a Shimadzu IR-Aﬃnity-1S FTIR.
Reference to spectroscopic data are given for known
compounds. Analytical HPLC was performed using an Agilent
1260 innity II equipped with a Zorbax SB-C18 2.1  50 mm
column and an Agilent 6120 Quadrupole LC/MS detector over
a 13 minute gradient elution. Preparatory HPLC was performed
using a Dionex UltiMate 3000 equipped with a YMC-Triart Prep
C18-S 250  19 mM column over a 55 min gradient elution. UV-
vis studies were performed on a Shimadzu UV-1800 spectro-
photometer as MeCN solutions (2.5 or 5  105 M). Photo-
physical data were obtained on a JobinYvon–Horiba Fluorolog
spectrometer tted with a JY TBX picosecond photodetection
module as MeCN solutions. Emission spectra were uncorrected
and excitation spectra were instrument corrected. The pulsed
source was a Nano-LED congured for 459 nm output operating
at 1 MHz. Luminescence lifetime proles were obtained using
the JobinYvon–Horiba FluoroHub single photon counting
module and the data ts yielded the lifetime values using the
provided DAS6 deconvolution soware. Quantum yield
measurements were obtained on aerated MeCN solutions of the
complexes using [Ru(bpy)3](PF6)2 in aerated MeCN as a stan-
dard (F ¼ 0.016).
Human broblast primary cell culture
Human derived skin broblast cells lines were obtained from
the Coriell Cell Repository (GM05399, Camden, NJ). Cells were
cultured as monolayers in Dulbecco's modied Eagles medium
(DMEM, Sigma, UK) supplemented with 10% fetal bovine serum
(FBS, PAN-Biotech, Aidenbach, Germany) and 1% L-glutamine
in a humidied incubator with 5% CO2 at 37 C. For all imaging
experiments low passage cells (P10-15) were seeded in 8-well
chamber slides (Thistle, IB-80826) at a density of 15 000 cells in
250 mL of media.
Cell staining with intracellular probes
To generate stock solutions, Ir-CMYC and Ir-PYR were resus-
pended in DMSO (nal concentration 10 mM) and stored at
20 C (it was noted that 3 freeze–thaws cycles did not appear to
reduce the compound signal). Stock solutions were diluted to
the stated concentrations in cell culture medium for incubation
with broblasts. The equivalent amount of DMSO (<0.5% total
volume) was added to controls for comparison. For nuclear
visualisation cells were counterstained for 10 minutes with
Hoechst 33342 diluted in cell culture media (1 mL mL1,
Thermo Fisher, UK). For non-live imaging, cells were xed in
cold 4% paraformaldehyde for 10 min at room temperature and
rinsed with PBS. For live-cell colocalization studies, cells were
incubated with Ir-PYR for 12 hours prior to counterstaining withChem. Sci.
Chemical Science Edge Article
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View Article OnlineHoechst 33342, and either LysoTracker-green DND-26 (L7528,
Thermo Fisher, UK), or CYTO-ID Autophagy detection kit 2.0
(175–0050, Enzo Life Sciences, UK), as per the manufacturer's
instructions. Briey, LysoTracker was diluted in cell culture
media to a nal concentration of 200 nM and le for 15 min at
37 C. CYTO-ID was diluted by adding 2 mL of CYTO-ID green
reagent in 1 mL of assay buﬀer and incubated for 30 min at
37 C. Aer organelle staining, cells were washed twice in DPBS
and immediately imaged in FluoroBrite DMEM (A1896701,
Thermo Fisher, UK) supplemented with 10% FBS.Monitoring cellular metabolic activity
Human broblasts were plated at 10 000 cells per well of a 96-
well plate (Cellbind) and treated with the indicated concentra-
tions of Ir-PYR, Ir-CMYC or DMSO. As a measure of cell viability
and metabolic activity, at 18 hours post compound addition
culture medium was removed and replaced with culture
medium containing 10 mg mL1 resazurin diluted in DPBS (10%
v/v). Aer a 4 hour incubation at 37 C, uorescence was
determined using a Molecular Devices Spectramax Gemini EM
plate reader (lex ¼ 445 nm; lem ¼ 585 nm).Imaging and localisation analysis
All wideeld uorescent microscopy was performed using
a Zeiss 35 tted with Cairn Optospin lter wheels at excitation
and emission ports, an Orca ash 4.0/4.2, sCMOS camera, Exfo
xCite multiband lightsource, and Micro-Manager soware.29
For confocal microscopy, live cells were imaged on an
inverted Leica DMIRE2 with TCS SP2 AOBS confocal system
using Leica AF soware in combination with a 405 nm diode
laser (Hoechst), a 458/476/488/514 nm argon multiline (Lyso-
Tracker and CYTO-ID), and a 594 nm HeNe (Ir-PYR). Images
were captured using a 40 oil-immersion objective coupled to
an additional 2 magnifying lens.30 During imaging, cells were
maintained at 37 C using an environmental chamber.
To generate intensity colocalization plots, images were
imported into Fiji as separate channels,31 and a line drawn
across an individual cell. Plot prole was used to generate
intensity of gray values across the ROI. Plots using data from
both channels was generated using Prism version 8.1.0
(GraphPad Soware, La Jolla California, USA). All experimental
cell data was repeated twice (n ¼ 2), with three technical repli-
cates per condition used in the individual experiment.Monitoring cellular metabolic activity
Human broblasts were plated at 10 000 cells per well of a 96-
well plate and treated with the various concentrations of Ir-PYR,
Ir-CMYC (5, 20, 80, 50, 100 mM) or the highest volume of
equivalent of DMSO only. As a measure of cell viability and
metabolic activity, at 18 hours post compound addition culture
medium was removed and replaced with culture medium con-
taining 10 mg mL1 resazurin diluted in DPBS (10% v/v).
Metabolically active cells reduce resazurin (blue and non-
uorescent) to resorun (pink and uorescent). Aer a 4 hour
incubation at 37 C, uorescence was determined usingChem. Sci.a Molecular Devices Spectramax Gemini EM plate reader (lex ¼
530 nm; lem ¼ 580 nm).
DNA-binding experiments
MOPS buﬀer was prepared by dissolving MOPS (3-(N-morpho-
lino)propanesulfonic acid, CAS[1132-61-2]), NaCl, and EDTA
(ethylenediaminetetraacetic acid disodium salt dihydrate, CAS
[6381-92-6]) (all obtained from Fisher and used as supplied) in
deionised water (Elga Purelab Flex), adjusting the pH to 7.0
using a NaOH solution (pH of the buﬀer was determined using
a Hanna Instruments pH210 microprocessor pH meter with
a VWR simple junction universal combined pH/reference elec-
trode) and making up the solution to 0.5 litre.
A stock solution of sh sperm DNA was prepared by dis-
solving approximately 0.1 g of sh sperm DNA in 10 mL of the
buﬀer. The resulting solution was dialysed (3.5 kDa MWCO,
Visking, Medicell International Ltd) against 0.5 litres of buﬀer.
Following dialysis, the DNA concentration was determined
using UV-visible spectroscopy (Shimadzu UV-1800 spectropho-
tometer) using an extinction coeﬃcient 3260nm ¼ 12 800
M(bp)1 cm1.32
Stock solutions containing 10 mM Ir-PYR or Ir-CMYC were
made as follows. For Ir-PYR, 1.01 mg was weighed out and
dissolved in 104.1 mL of DMSO. For Ir-CMYC, 0.6 mg was
weighed out and dissolved in 31.6 mL of DMSO.
Circular dichroism titrations were carried out using an
Applied Photophysics Chirascan spectrophotometer thermo-
stated at 25 C. First, 2500 mL of buﬀer was placed in a 1 cm
pathlength quartz cuvette (Hellma) and a spectrum was recor-
ded between 700 and 230 nm. Next, between 10 and 15 mL
(typically 12.5 mL) of the stock solution of the iridium complex
in DMSO was added to the buﬀer and a spectrum was recorded.
Subsequently, 5 aliquots of 20 mL, 4 aliquots of 50 mL and 2
aliquots of 100 mL (i.e. a cumulative added volume of 500 mL) of
the DNA stock solution were added and a spectrum was recor-
ded aer every addition.
DNA binding – data analysis results
Spectra and titrations were plotted in OriginLab Origin 2019b.
The titration data were analysed globally for each complex using
an in-house written version of the multiple independent
binding sites model which also explicitly takes ligand concen-
trations into account.28 Exploratory data analysis showed that
binding aﬃnity and binding site size could not be determined
separately from this data, as is usual for relatively weak binding.
The binding site size (n) was therefore set to three base pairs for
both complexes. The molar ellipticity of the free ligand (qm,free/
mdeg) was restricted to 0, i.e. no CD signal in the absence of DNA
while the background ellipticity at the wavelength of interest
(qbackground,x nm) was an optimisable parameter to address the
eﬀects of noise on the data. The data analysis thus provided
optimised values for the equilibrium constant (K), the changes
in molar ellipticity upon binding at the wavelengths of interest
(Dqm,x nm) and the background ellipticities at the wavelengths of
interest (qbackground,x nm). These values are summarised in
Table S1.†This journal is © The Royal Society of Chemistry 2020
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